{
    "Trade/Device Name(s)": [
        "HemosIL Liquid Anti-Xa"
    ],
    "Submitter Information": "Instrumentation Laboratory Company",
    "510(k) Number": "K213464",
    "Predicate Device Reference 510(k) Number(s)": [
        "K090209",
        "DEN190032"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KFF",
        "QLU"
    ],
    "Summary Letter Date": "June 3, 2022",
    "Summary Letter Received Date": "June 6, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7525",
        "21 CFR 864.7295"
    ],
    "Regulation Name(s)": [
        "Heparin Assay",
        "Anti-factor Xa Activity Test System, Apixaban"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Unfractionated heparin",
        "Low molecular weight heparin",
        "Apixaban"
    ],
    "Specimen Type(s)": [
        "3.2% citrated human plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family",
        "ACL TOP Family 50 Series"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay"
    ],
    "Methodologies": [
        "One stage chromogenic assay",
        "Synthetic chromogenic substrate",
        "Factor Xa inactivation"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL Liquid Anti-Xa automated chromogenic assay for quantifying heparin and apixaban in citrated plasma using ACL TOP analyzers.",
    "Indications for Use Summary": "Automated chromogenic assay for quantitative determination of unfractionated heparin, low molecular weight heparin, and apixaban in adult 3.2% citrated plasma, for use on ACL TOP Family and 50 Series analyzers, aiding management in situations such as risk for major bleeding or bleeding episodes.",
    "fda_folder": "Hematology"
}